Latest Content

In today's Pharmaceutical Executive Daily, a federal judge blocks RFK Jr.'s reconstituted vaccine advisory committee and halts its policy changes, a new analysis breaks down what recent Gartner predictions on AI mean for healthcare marketers, and the FDA approves Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis.

The funding rounds are part of a broader effort to advance next-generation T-cell engager platforms targeting cancers.

FDA has approved Icotyde as the first oral targeted therapy for moderate-to-severe plaque psoriasis, offering adults and adolescents a once-daily pill that blocks the IL-23 receptor.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, mentions how eClinical Solutions positioned its elluminate platform as part of an effort to help sponsors meet heightened evidence and oversight demands.

Faruk Capan provides insights into the future of proprietary AI platforms.

New technologies are impacting the speed-to-therapy within hub services.

Manufacturers are rethinking patient assistance program architecture amid the economic pressures of the Inflation Reduction Act.

The ruling places a hold on any decisions made by the council, although the government does plan to appeal the ruling.

Dave Rusher, CCO at Aravo, explains the relationship between large, publicly available LLMs and how private LLMs might benefit the pharma industry.

Jeanne Marrazzo, MD, FIDSA, MPH, CEO of the Infectious Diseases Society of America discusses the growing measles outbreak in the United States, which has surpassed 730 cases and represents the largest surge in decades.

RDEP is a sign that regulators acknowledge that rare disease is a unique space that requires special attention.

Vera Pomerantseva, Director of Product Management for RBQM, eClinical Solutions, touched on AI's growing role in clinical development appearing to be part of a broader effort to strengthen trial evidence.

In today's Pharmaceutical Executive Daily, ongoing conflict in the Middle East is straining pharmaceutical supply routes to the Gulf region, Sentynl Therapeutics enters a licensing agreement with PRG-ST to advance a progerin-targeting therapy for progeria, and a new analysis examines the innovations, integration challenges, and early hurdles shaping the emerging biotech landscape.